← Leaderboards
Dennis Neil Bourdette
Oregon Health And Science University
$3,049,651
Attributed
$3,080,678
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $987.1K · FY2008–16$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$3,080,678 · 4
VA$0 · 2
By mechanism
R01$1,667,533 · 1
P30$1,263,092 · 1
M01$87,998 · 1
R03$62,055 · 1
I01$0 · 2
Top collaborators
- Michael A Forte2 shared
Most similar at Oregon Health And Science University
Same institution · by research overlap
- John M Denu$18,836,664
- Jau-Shin Lou$1,389,037
- Judy L Cameron$15,771,053
- Michael A Forte$6,128,057
- Jesse V Jacobs$146,321
Others in their field
Top investigators on “Multiple Sclerosis”
- David A. Hafler · Brigham And Women'S Hospital$33,720,341
- Vijay K Kuchroo · Brigham And Women'S Hospital$32,935,587
- Stephen L Hauser · University Of California San Francisco$32,469,388
- Katerina Akassoglou · University Of California San Diego$24,525,425
- Abdolmohamad Rostami · Thomas Jefferson University$23,969,638
- Stephen D Miller · Northwestern University$23,969,272
Research focus
Multiple SclerosisPharmaceutical PreparationsNeuraxisAxonBrainIn VitroResponseAxonal DegenerationSiteMitochondriaProductionCostLifeAttentionMolecularExperimental Autoimmune EncephalomyelitisInjuryPreventInflammationInflammatoryBaseInflammation MediatorsDemyelinationsDisability
Grant awards (18)
A randomized trial of a formal group program for fatigue in multiple sclerosis$0
I01 · FY2016 · VA · contact PI
A randomized trial of a formal group program for fatigue in multiple sclerosis$0
I01 · FY2015 · VA · contact PI
A randomized trial of a formal group program for fatigue in multiple sclerosis$0
I01 · FY2015 · VA · contact PI
A randomized trial of a formal group program for fatigue in multiple sclerosis$0
I01 · FY2015 · VA · contact PI
Small Molecules Targeting the Mitochondrial Permeability Transition$30,555
R03 · FY2013 · DA
Lipoic Acid Therapy for Experimental Autoimmune Encephalomyelitis$0
I01 · FY2013 · VA · contact PI
Mitochondrial modulation for neuroprotection in a model of multiple sclerosis$330,138
R01 · FY2012 · NS · contact PI
Small Molecules Targeting the Mitochondrial Permeability Transition$31,500
R03 · FY2012 · DA
Lipoic Acid Therapy for Experimental Autoimmune Encephalomyelitis$0
I01 · FY2012 · VA · contact PI
Mitochondrial modulation for neuroprotection in a model of multiple sclerosis$330,138
R01 · FY2011 · NS · contact PI
Lipoic Acid Therapy for Experimental Autoimmune Encephalomyelitis$0
I01 · FY2011 · VA · contact PI
Jungers Center New Faculty Recruitment in Genetic Models of Axonal Degeneration$653,579
P30 · FY2010 · NS · contact PI
Mitochondrial modulation for neuroprotection in a model of multiple sclerosis$333,507
R01 · FY2010 · NS · contact PI
Jungers Center New Faculty Recruitment in Genetic Models of Axonal Degeneration$609,513
P30 · FY2009 · NS · contact PI
Mitochondrial modulation for neuroprotection in a model of multiple sclerosis$336,875
R01 · FY2009 · NS · contact PI
Lipoic Acid Therapy for Experimental Autoimmune Encephalomyelitis$0
I01 · FY2009 · VA · contact PI
Mitochondrial modulation for neuroprotection in a model of multiple sclerosis$336,875
R01 · FY2008 · NS · contact PI
Study to evaluate the role of an oral antioxidant, alpha lipoic acid in MS$87,998
M01 · FY2004 · RR